These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

231 related articles for article (PubMed ID: 8899847)

  • 1. Absorption and presystemic metabolism of selegiline hydrochloride at different regions in the gastrointestinal tract in healthy males.
    Barrett JS; Szego P; Rohatagi S; Morales RJ; De Witt KE; Rajewski G; Ireland J
    Pharm Res; 1996 Oct; 13(10):1535-40. PubMed ID: 8899847
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Pharmacokinetics and bioequivalence of the main metabolites of selegiline: desmethylselegiline, methamphetamine and amphetamine after oral administration of selegiline.
    Mascher HJ; Kikuta C; Millendorfer A; Schiel H; Ludwig G
    Int J Clin Pharmacol Ther; 1997 Jan; 35(1):9-13. PubMed ID: 9021435
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pharmacokinetics of selegiline, R-methamphetamine, R-amphetamine, and desmethylselegiline in oral fluid after a single oral administration of selegiline.
    Chen L; Shen B; Wang S; Yu Y; Yan H; Shi Y; Duan G; Xiang P
    Drug Test Anal; 2019 Jun; 11(6):898-905. PubMed ID: 30614204
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Multiple-dose pharmacokinetics of selegiline and desmethylselegiline suggest saturable tissue binding.
    Laine K; Anttila M; Huupponen R; Mäki-Ikola O; Heinonen E
    Clin Neuropharmacol; 2000; 23(1):22-7. PubMed ID: 10682227
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Integrated pharmacokinetic and metabolic modeling of selegiline and metabolites after transdermal administration.
    Rohatagi S; Barrett JS; DeWitt KE; Morales RJ
    Biopharm Drug Dispos; 1997 Oct; 18(7):567-84. PubMed ID: 9330778
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A new formulation of selegiline: improved bioavailability and selectivity for MAO-B inhibition.
    Clarke A; Brewer F; Johnson ES; Mallard N; Hartig F; Taylor S; Corn TH
    J Neural Transm (Vienna); 2003 Nov; 110(11):1241-55. PubMed ID: 14628189
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Pharmacokinetic evaluation of a selegiline pulsatile oral delivery system.
    Rohatagi S; Barrett JS; DeWitt KE; Lessard D; Morales RJ
    Biopharm Drug Dispos; 1997 Nov; 18(8):665-80. PubMed ID: 9373724
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Bioavailability of two selegiline hydrochloride tablet products.
    Müller FO; Schall R; Hundt HK; Joubert A; Middle MV; Muir AR; Duursema L; Groenewoud G; Swart KJ
    Arzneimittelforschung; 1996 Nov; 46(11):1037-40. PubMed ID: 8955861
    [TBL] [Abstract][Full Text] [Related]  

  • 9. CYP2C19 polymorphism is not important for the in vivo metabolism of selegiline.
    Laine K; Anttila M; Nyman L; Wahlberg A; Bertilsson L
    Eur J Clin Pharmacol; 2001 May; 57(2):137-42. PubMed ID: 11417445
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Desmethylselegiline, a metabolite of selegiline, is an irreversible inhibitor of monoamine oxidase type B in humans.
    Heinonen EH; Anttila MI; Karnani HL; Nyman LM; Vuorinen JA; Pyykkö KA; Lammintausta RA
    J Clin Pharmacol; 1997 Jul; 37(7):602-9. PubMed ID: 9243353
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The Effect of Dosing Regimen and Food on the Bioavailability of the Extensively Metabolized, Highly Variable Drug Eldepryl(®) (Selegiline Hydrochloride).
    Barrett JS; Rohatagi S; DeWitt KE; Morales RJ; DiSanto AR
    Am J Ther; 1996 Apr; 3(4):298-313. PubMed ID: 11862265
    [TBL] [Abstract][Full Text] [Related]  

  • 12. CYP2D6 polymorphism is not crucial for the disposition of selegiline.
    Scheinin H; Anttila M; Dahl ML; Karnani H; Nyman L; Taavitsainen P; Pelkonen O; Bertilsson L
    Clin Pharmacol Ther; 1998 Oct; 64(4):402-11. PubMed ID: 9797797
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Pharmacokinetics and safety of a selegiline transdermal system relative to single-dose oral administration in the elderly.
    Barrett JS; Hochadel TJ; Morales RJ; Rohatagi S; DeWitt KE; Watson SK; DiSanto AR
    Am J Ther; 1996 Oct; 3(10):688-98. PubMed ID: 11862224
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Selegiline pharmacokinetics are unaffected by the CYP3A4 inhibitor itraconazole.
    Kivistö KT; Wang JS; Backman JT; Nyman L; Taavitsainen P; Anttila M; Neuvonen PJ
    Eur J Clin Pharmacol; 2001 Apr; 57(1):37-42. PubMed ID: 11372588
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Pharmacokinetics and absolute bioavailability of selegiline following treatment of healthy subjects with the selegiline transdermal system (6 mg/24 h): a comparison with oral selegiline capsules.
    Azzaro AJ; Ziemniak J; Kemper E; Campbell BJ; VanDenBerg C
    J Clin Pharmacol; 2007 Oct; 47(10):1256-67. PubMed ID: 17715422
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Ciprofloxacin absorption in different regions of the human gastrointestinal tract. Investigations with the hf-capsule.
    Harder S; Fuhr U; Beermann D; Staib AH
    Br J Clin Pharmacol; 1990 Jul; 30(1):35-9. PubMed ID: 2390430
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Gastrointestinal absorption of pravastatin in healthy subjects.
    Triscari J; O'Donnell D; Zinny M; Pan HY
    J Clin Pharmacol; 1995 Feb; 35(2):142-4. PubMed ID: 7751423
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Phase 1 and phase 2 metabolic activities along the small intestine in adult male sheep.
    Maté L; Virkel G; Lifschitz A; Sallovitz J; Ballent M; Lanusse C
    J Vet Pharmacol Ther; 2010 Dec; 33(6):537-45. PubMed ID: 21062305
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effect of erythromycin on the absorption of fexofenadine in the jejunum, ileum and colon determined using local intubation in healthy volunteers.
    Petri N; Borga O; Nyberg L; Hedeland M; Bondesson U; Lennernas H
    Int J Clin Pharmacol Ther; 2006 Feb; 44(2):71-9. PubMed ID: 16502766
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Risedronate gastrointestinal absorption is independent of site and rate of administration.
    Mitchell DY; Eusebio RA; Dunlap LE; Pallone KA; Nesbitt JD; Russell DA; Clay ME; Bekker PJ
    Pharm Res; 1998 Feb; 15(2):228-32. PubMed ID: 9523308
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.